Currency in USD Follow 2W 10W 9M 1. Theratechnologies inc. Presented in part at the XVI International AIDS Conference; August 13–18, 2006; Toronto, Canada (abstracts TUP30058 AND THLB0218). Theratechnologies présente des données démontrant la surexpression de la sortiline (SORT1) dans plusieurs types de tumeurs au 34e symposium de l’EORTC-NCI-AACRVice President, Communications and Corporate Affairs. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691Theratechnologies Announces Amendment to its Term Loan Facility With Affiliates of Marathon Asset Management. By exploiting the SORT1 function in ligand internalization, a new anticancer treatment strategy was designed to target SORT1‐positive TNBC‐derived cells both in vitro and in two in vivo tumor xenografts. 's motion for leave to commence. It is the Company’s proprietary peptide linked to. ET. com uses cookies on this site. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Get the latest Theratechnologies Inc (THTX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. TH | February 28, 2023. Stockhouse. The business had revenue of $27. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will report financial results and provide a business update for. Theratechnologies Inc. The company reported ($0. THERATECHNOLOGIES INC. MONTREAL, April 03, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies Inc. 71. 49%) At close: 04:00PM EST 1. We also use them to share usage. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 00 in the next twelve months. It also helps investors analyze the systematic and unsystematic risks associated with investing in Theratechnologies over a specified time horizon. (TSX: TH, Forum) has long been a favourite among Healthcare Bullboard posters who have been following its developments to commercialize innovative therapies. We currently market prescription products for people with HIV in the United States. com uses cookies on this site. Theratechnologies Appoints New Board Member. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today presented preclinical data that demonstrate the potential utility of its lead investigational. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. Their average twelve-month price target is $36. ( THTX 3. 28, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Further. Theratechnologies is currently developing a platform of proprietary peptides called SORT1+ Technology TM for cancer drug development targeting SORT1 receptors. Cookies are used to offer you a better browsing experience and to analyze our traffic. MONTREAL, Nov. ("Theratechnologies" or the "Company"). By continuing to use our service, you agree to our use of cookies. MONTREAL, Jan. Further information about Theratechnologies is available on the Company’s website at on SEDAR+ at and. (Translation of registrant’s name into English) 2310 Alfred-Nobel Boulevard . By continuing to use our service, you agree to our use of cookies. com uses cookies on this site. Investor inquiries: Elif McDonald. About Theratechnologies Theratechnologies (TSX:TH) is a specialty pharmaceutical company addressing unmet medical needs to promote healthy ageing and an improved quality of life among HIV patients. (2022-05-31 | TSX:TH) Theratechnologies Announces New Head of Investor Relations. (2021-11-23 | TSX:TH) Theratechnologies Announces Renewal of Shelf Prospectus and Registration Statement; At-The-Market Facility to be Extended. We also use them to share usage. Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced today that it will report financial results for its second quarter of fiscal 2022 ended May 31 on Thursday, July 14, 2022. Theratechnologies (TH) has submitted a supplemental biologics license application (sBLA) to the U. MONTREAL, April 14, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. com. Theratechnologies stated the primary endpoint measured a 90 per cent confidence interval of the IM injection to IV injection (0. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. European Headquarters. By continuing to use our service, you agree to our use of cookies. TO) on CEO. m. Theratechnologies's earnings have been declining at an average annual rate of -35. 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691. 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. WELCOME TO SEDAR+ File, disclose and search for issuer information in Canada’s capital markets Search SEDAR+ All public disclosure documents Reporting Issuers List Filing organizations from all jurisdictions Disciplined List People and companies under disciplinary action Cease Trade Orders People and companies restricted from trading securities Sign. 89 52. Cookies are used to offer you a better browsing experience and to analyze our traffic. (NASDAQ:THTX) Q2 2022 Earnings Conference Call July 14, 2021 8:30 AM ET. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company will present data from tissue microarrays showing high. THTX earnings call for the period ending February 29, 2020. Their THTX share price targets range from $36. It is the Company’s proprietary peptide linked to docetaxel – a commonly used cytotoxic agent used to treat many cancers. Theratechnologies Inc. 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. Stockhouse. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. NEW YORK, Dec. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its third quarter of fiscal 2022 ended August 31, on Thursday, October 13. These pharmaceuticals. 30, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies, Inc. By continuing to use our service, you agree to our use of cookies. VANCOUVER, British Columbia, Nov. 3. 6. (2022-02-10 | TSX:TH) Theratechnologies to Announce Financial Results for Its Fourth Quarter and Full Fiscal Year 2021. $44. Unveiling Silvercorp's golden potential at the Ying Mining District. a biopharmaceutical company focused on the development and commercialization of innovative therapies, today initiated enrollment of patients in the basket portion of the first-in-human study of TH1902, Theratechnologies’ investigational lead peptide drug conjugate (PDC) for the treatment of sortilin-expressing. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. By continuing to use our service, you agree to our use of cookies. Stockhouse. Theratechnologies Inc. TH | Complete Theratechnologies Inc. com uses cookies on this site. Free cash flow. Cookies are used to offer you a better browsing experience and to analyze our traffic. T. communications@theratech. (TSX: TH, Forum) noted that its Q1 2022 consolidated sales grew 20%, supported by 35% growth in sales of EGRIFTA SV formulation. It is highly expressed in cancer cells compared to healthy tissue, which makes SORT1 an. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced publi. Cookies are used to offer you a better browsing experience and to analyze our traffic. (TSX: TH) announced today that the Supreme Court of Canada has granted its appeal and dismissed 121851 Canada Inc. By continuing to use our service, you agree to our use of cookies. H4S 2B4 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ¨ Form 40-F xMain number: 514-336-7800. THERATECHNOLOGIES INC. T. The reported ($0. com uses cookies on this site. View recently published Stock News reports from independent reports and journalists. (2021-01-11 | TSX:TH) Theratechnologies Announces US$40 Million Bought-Deal Public Offering of Units. Gary Littlejohn. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies announced today that it will report its financial results for the second quarter of fiscal 2021 ended May 31, 2021 on Wednesday. com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. 19, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Stockhouse. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has established an at-the-market ("ATM") equity program allowing Theratechnologies to issue and sell up to US $50 million common shares from. TMX Group Limited and its affiliates do not endorse or recommend any securities issued by any companies identified on, or linked through, this site. Theratechnologies Inc (Theratechnologies) is a biopharmaceutical company that focuses on the discovery and development of drugs for people with orphan medical conditions. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. By continuing to use our service, you agree to our use of cookies. Biopharma Theratechnologies (NASDAQ:THTX) Friday announced that a study evaluating an intramuscular (IM) method of administration for its therapy, Trogarzo, did not meet the primary endpoint. 4% from the stock's current price. MONTREAL, May 09, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. We also use them to share usage information with our partners. FY2022 top line revenue expected to end the year at ~$80 million, in line with previously announced revenue guidance; FY2023 revenue guidance range set between $90 million and $95 million, ending the new year on a solid path to positive cash. About Theratechnologies Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of. Cookies are used to offer you a better browsing experience and to. Vancouver, Canada –– TheNewswire - April 7, 2022 - Teuton Resources Corp. 26, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. . $30. (2022-09-19 | TSX:TH) Theratechnologies to Present at the Cantor Oncology, Hematology & HemeOnc Conference. Stockhouse. - 2023 Q3 positive adjusted EBITDA to be achieved. By continuing to use our service, you agree to our use of cookies. 81 million for the quarter. 2022 Revenue Guidance Theratechnologies anticipates fiscal 2022 revenue to be in the range of $79 million and $84 million for full fiscal 2022, or growth of the commercial portfolio to be in the. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share. Stockhouse. com uses cookies on this site. MONTREAL, March 31, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies Announces First Patient Dosed in Phase 1 Clinical Trial of TH1902 for Sortilin Positive Solid Tumors. T. [email protected] Inc: Overview. Volume has increased on the last day along with the price, which is a. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced receipt of the 2023 Industrial Research Sectoral Group (RSRI) Innovation Award from the CQDM (for. MONTREAL, July 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691. Further information about Theratechnologies is available on the Company's website at , on SEDAR at and on EDGAR at . 71%. We also use them to share usage. (THTX) Stock Price, Quote, latest community messages, chart, news and other stock related information. If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or. Theratechnologies Unveils New Positive Data for Its Investigational Peptide-Drug Conjugates Targeting Sortilin Positive Cancers Stockhouse. H4S 2B4 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F x Form 40-F ¨Theratechnologies has established its SORT1+ Technology™ platform as an engine for the development of proprietary peptide-drug conjugates (PDCs) that target the sortilin (SORT1) receptor, which is expressed in multiple tumor types. com uses cookies on this site. Senior Director, Investor Relations. Theratechnologies was founded in 1993 and is headquartered in Montreal, Canada. 03) EPS for the quarter, beating the consensus estimate of ($0. Story. Find the latest Theratechnologies Inc. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. E-Poster website launch date and time: Saturday, April 10, 2021, 8:30 AM. Theratechnologies Announces 1-for-4 Reverse Stock Split. TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (Sort1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth Sep 13. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650WELCOME TO SEDAR+ File, disclose and search for issuer information in Canada’s capital markets Search SEDAR+ All public disclosure documents Reporting Issuers List Filing organizations from all jurisdictions Disciplined List People and companies under disciplinary action Cease Trade Orders People and companies restricted from trading securities Sign. 31K. Biopharmaceutical company Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has established an at-the-market ("ATM") equity program allowing Theratechnologies to. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the. 1-514-336-7800. Theratechnologies Inc. MONTREAL, Aug. The company’s marketed products include Egrifta SV is indicated to reduce excess abdominal fat in human immunodeficiency virus (HIV. -based clinical sites participating in the conduct of the Phase. By continuing to use our service, you agree to our use of cookies. (“Theratechnologies” or the “Company”) (TSX: TH) today announced that it has applied to list its common shares on NASDAQ. TH1902 is currently Theratechnologies’ lead investigational peptide drug conjugate candidate for the treatment of cancer derived from its SORT1+ Technology™. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced an update on the plan to amend and optimize the protocol of its Phase 1 oncology. 2% for this period. 1M. . . Cookies are used to offer you a better browsing experience and to analyze our traffic. About Theratechnologies Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 0. We also use them to share usage. (2020-10-16 | TSX:TH) Theratechnologies Appoints Two New Board Members. Cookies are used to offer you a better browsing experience and to. 8. A live webcast of Dr. (Translation of registrant’s name into English) 2310 Alfred-Nobel Boulevard . BioSyent then managesthese products through the regulatory process and product registration (approval); and once approved, BioSyent markets these products throughout Canada. The abstract and poster can be found on Theratechnologies’ website. Betteryear2. 2% to $21. By continuing to use our service, you agree to our use of cookies. 75. We also use them to share usage information with our partners. By continuing to use our service, you agree to our use of cookies. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced publi. com uses cookies on this site. MONTREAL, July 23, 2021 /CNW Telbec/ - Theratechnologies Inc. “Theratechnologies’ commitment to investors at the beginning of 2023 has been to remain steadfast in delivering on key financial objectives, particularly to achieve positive adjusted EBITDA by the end of the current fiscal year,” said Philippe Dubuc, Senior Vice President and Chief Financial Officer at Theratechnologies. (2022-04-27 | TSX:TH) Theratechnologies to Focus Its Commercialization Activities on the North American Territory. 1300 (+9. Theratechnologies Inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. MONTREAL, June 30, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. If you have JavaScript enabled then this page should refresh automatically, if it does not then please tap the button below. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. com uses cookies on this site. The financial results presented in this press release are taken from the. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on. TH 48% v4,15M c1. Cookies are used to offer you a better browsing experience and to analyze our traffic. 38. Share your ideas and get valuable. 06 million, an increase of 14. Theratechnologies’ CFO to Attend Cantor Global Healthcare Conference in New York City. Theratechnologies Draws Down on US$20 Million Second Tranche Under its Term Loan Facility With Affiliates of Marathon Asset Management. 69 to $1. 124. (2022-07-27 | TSX:TH) Theratechnologies Announces Closing of Funding of $40 Million Under the Terms of its Credit Agreement. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (Theratechnologies, or the Company (on a consolidated basis)) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on. . GUD | Complete Knight Therapeutics Inc. Focused on small-cap companies and sectors. TH | February 28, 2023. Statut du système de négociation. 2 million. Cookies are used to offer you a better browsing experience and to analyze our traffic. $109. This news release constitutes a "designated news release" for the purposes of. 2015 Peel St 11TH Fl, Montreal, Quebec, H3A 1T8, Canada. Patient assistance: 833-238-4372. 2. We also use them to share usage. By continuing to use our service, you agree to our use of cookies. com uses cookies on this site. MONTREAL, Oct. TORONTO, May 19, 2023. Investor Relations. 01, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Overview Stock Screener Earnings Calendar Sectors Nasdaq | THTX U. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and. Apr 14, 2020, 8:30 a. In the United States, Trogarzo ® (ibalizumab. With the company starting 2023 with 8,725 employees, that’s an 11. 1-438. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that all five of the U. . (2020-10-22 | TSX:TH) Theratechnologies to Present at Upcoming Investor Conferences on October 29 and November 10, 2020. MONTREAL, April 18, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. About Theratechnologies Theratechnologies (Nasdaq: THTX) (TSX: TH) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. We also use them to share usage information with our partners. T. We currently market prescription products for people with HIV in the United States. Stockhouse. By continuing to use our service, you agree to our use of cookies. (TSX: EXRO) (OTCQB: EXROF) (the "Company" or "Exro" ), a leading clean technology company which has developed a new class of power electronics for electric motors and powertrains, announced today its financial results for the three months ended March 31, 2022. 01, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 86%. 49) by $0. Theratechnologies Inc. com. (TSX:TH) announced new data from a tissue microarrays study which demonstrated high expression of sortilin 1 in solid tumors. Join the discussion: Find out what everybody’s saying about this stock on the Theratechnologies Bullboard, and check out the rest of Stockhouse’s stock forums and message boards. Theratechnologies Inc. 02, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. About Theratechnologies. (2015-05-15 | TSX:TH) Authorization to Discontinue Class Action Proceedings Against Theratechnologies Granted. -986. Theratechnologies Appoints New Board Member. By continuing to use our service, you agree to our use of cookies. We also use them to share usage. TH Stock Message Board for Investors. Cookies are used to offer you a better browsing experience and to analyze our traffic. Cookies are used to offer you a better browsing experience and to analyze our traffic. Lead drug EGRIFTA (tesamorelin for injection) is being marketed for the reduction of excess abdominal fat in HIV-infected patients with. MONTREAL, Jan. View Company Info for Free. -4. Cookies are used to offer you a better browsing experience and to analyze our traffic. $30. 16%. OTCQX – this is the premium tier of OTC stocks. " The 12-month stock price forecast is $18. Forecast to breakeven in 2024 Jul 15. 7 ( 1D) About THTX In 2022, THTX's revenue was 80. Ibalizumab-uiyk (Trogarzo) is a medical infusion treatment for HIV infection in adults for whom other HIV medicines have not worked. M. The company reported ($0. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. It engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). 14, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Biopharmaceutical company Theratechnologies Inc. 35 as of 10:41 a. 5000 +0. A high-level overview of Theratechnologies Inc. TORONTO, May 19, 2023 /CNW/ - This press release is being disseminated as required by. 617-356-1009. MONTREAL, Feb. (2021-12-06 | TSX:TH) Theratechnologies Submits Supplemental Biologics License Application to FDA Advancing Development of IV Push Trogarzo® for Patients Living With HIV. Herein, we report. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies,. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its first quarter 2023 ended February 28, on Wednesday, April. Who is Theratechnologies. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Get the latest Sernova Corp (SVA) real. Cookies are used to offer you a better browsing experience and to analyze our traffic. By continuing to use our service, you agree to our use of cookies. MONTREAL, Feb. MONTREAL, July 07, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. MONTREAL, Sept. By continuing to use our. Cookies are used to offer you a better browsing experience and to analyze our traffic. By continuing to use our service, you agree to our use of cookies. com uses cookies on this site. TH | September 26, 2023. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX) today announced the publication of a preclinical study demonstrating the in vitro and in vivo efficacy of TH1902, an investigational sortilin (SORT1)-targeted peptide-drug conjugate, in inhibiting ovarian cancer and triple-negative breast cancer (TNBC. , that crews have been mobilized to prepare for the 2022 exploration program at the Treaty Creek property, located in the heart of the. Canada’s largest financial portal for Canadian small-cap investors is right here at Stockhouse where our Bullboards are a leading forum. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that it plans to pursue Phase 3 clinical development of tesamorelin for the treatment of Non-Alcoholic Steatohepatitis (NASH) in. About Theratechnologies Theratechnologies (Nasdaq: THTX) (TSX: TH) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. Theratechnologies is leveraging its SORT1+ Technology™ to develop a new class of therapy that targets sortilin (SORT1)-positive cancers by linking anticancer drugs to proprietary peptides that specifically bind to the sortilin receptor. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company will present data from tissue microarrays showing high expression of. Amendments Allow Theratechnologies to Maintain Minimum Liquidity of US$15 Million up to and until October 31, 2023. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies,. Wainwright NASH Investor Conference. Agreement in principle on key amendments to loan. (TSX-V: TLT, Forum) has demonstrated proof-of-concept for its Canadian-made COVID-19 vaccine. Further. F8 formulation intended to replace EGRIFTA SV® with simplified dosing for the treatment of excess abdominal fat in adults with HIV and lipodystrophy. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. We also use them to share usage information with our partners. - Q3 2022 North American Revenue Growth of 19%. (TSE:TH) posted its quarterly earnings data on Tuesday, September, 26th. Theratechnologies is currently developing a platform of proprietary peptides called SORT1+ Technology TM for cancer drug development targeting SORT1. 617-356-1009. Conjugating the short peptide with various anti-cancer agents allows for. com uses cookies on this site. , Senior Vice President and Chief Medical Officer, Theratechnologies commented, “The exciting new data in triple negative breast and ovarian cancer demonstrate. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that President and CEO, Paul Lévesque has issued an open letter to. One reason for that is that this tier does not include penny stocks. For investor inquiries: Leah Gibson. Stockhouse. 's motion for leave to commence. 69, 1. Theratechnologies was founded in 1993 and currently employs more than 150 people in Canada, the United States and Europe.